tiprankstipranks
Pharvaris (PHVS)
NASDAQ:PHVS
US Market
PHVS
Pharvaris
RESEARCH TOOLSreports
Want to see PHVS full AI Analyst Report?

Pharvaris (PHVS) Stock News & Sentiment

175 Followers
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
Premium
Ratings
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
10d ago
PHVS
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
Premium
Ratings
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
16d ago
PHVS
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
Premium
Market News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
18d ago
ANET
BCRX
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
Premium
Ratings
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
25d ago
PHVS
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
Premium
Company Announcements
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
29d ago
6K
PHVS
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
Premium
Ratings
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
4M ago
PHVS
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
Premium
Company Announcements
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
4M ago
6K
PHVS
More PHVS News >

PHVS News on the Web

Pharvaris price target raised to $52 from $48 at JonesResearch
TipRanks News
Bullish
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
TipRanks News
Bullish
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
The Motley Fool
Bearish
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
TipRanks News
Neutral
Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and Pharvaris (PHVS)
TipRanks News
Neutral
Pharvaris initiated with an Outperform at Wolfe Research
TipRanks News
Bullish
Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
PHVS
Sector Average
Media Buzz
This Week2 articles
Weekly Average3.75 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PHVS’s Media Buzz Sentiment?
2 articles about PHVS were published this week. In an average week, 3.75 articles are published.
    What is PHVS’s weekly average amount of articles?
    In an average week, 3.75 articles about PHVS are published.
      What is PHVS’s News Sentiment?
      100% of articles about PHVS were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week